Company Name Atara Biotherapeutics
Mailing Address 2659 Townsgate Road Thousand Oaks, CA 91361
Company Description Our mission is to develop novel treatment options for patients with severe and life-threatening conditions that have been underserved by scientific innovation. We are investigating therapies targeting unique pathways to pause or reverse patients’ underlying diseases.
Proceeds Purposes Proceeds will be used to accelerate the clinical development of Atara’s two lead programs, PINTA 745 and STM 434, which are expected to generate new clinical data within the next 18 months. PINTA 745 is a myostatin inhibiting peptibody in Phase 2 development as a potential treatment for protein energy wasting (PEW), a form of inflammation, malnutrition and muscle wasting in patients with end-stage renal disease.